OxTalks will soon move to the new Halo platform and will become 'Oxford Events.' There will be a need for an OxTalks freeze. This was previously planned for Friday 14th November – a new date will be shared as soon as it is available (full details will be available on the Staff Gateway).
In the meantime, the OxTalks site will remain active and events will continue to be published.
If staff have any questions about the Oxford Events launch, please contact halo@digital.ox.ac.uk
New therapies that promote antitumor immunity have been recently developed. Most
of these immunomodulatory approaches have focused on enhancing T-cell responses,
either by targeting inhibitory pathways with immune checkpoint inhibitors, or by
targeting activating pathways, as with chimeric antigen receptor T cells or bispecific
antibodies. Although these therapies have led to unprecedented successes, only a
minority of patients with cancer benefit from these treatments, highlighting the need to
identify new cells and molecules that could be exploited in the next generation of
immunotherapy. Given the crucial role of innate immune responses in immunity,
harnessing these responses opens up new possibilities for long-lasting, multilayered
tumor control. We will present innovative anti-tumor therapies based on the
manipulation of Natural Killer cells in particular via Antibody-based NK cell Engager
Therapeutics (ANKETs).
